StockNews.AI
QNRX
StockNews.AI
208 days

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

1. Skinvisible grants Quoin exclusive rights for Netherton Syndrome treatment. 2. Quoin's progress could enhance Skinvisible's market position and royalties.

2m saved
Insight
Article

FAQ

Why Bullish?

The exclusive licensing agreement signals potential revenue growth for Skinvisible, which may positively influence QNRX.

How important is it?

The developments in rare disease treatments can significantly affect market dynamics, impacting stock prices.

Why Long Term?

As Quoin progresses in treatments, it could lead to sustained revenue over time, benefiting related stocks.

Related Companies

SKVIQNRX
LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB:SKVI), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces significant achievements in 2024 and 2025, through its licensee Quoin Pharmaceuticals' progress in Netherton Syndrome treatment. Skinvisible granted Quoin an exclusive, royalty-bearing license to its technology for use in select rare skin diseases and for the right to use its proprietary formula for Netherton Syndrome.

Related News